A framework to support new product introduction in national health systems
Featured Product:
Pediatric Dolutegravir (10 mg) Dispersible, Scored Tablets
Latest Pediatric DTG and Pediatric ALD Resources
Building on the 2020 World AIDS Day announcement on pediatric dolutegravir (10mg) dispersible, scored tablets (pDTG), CHAI is pleased to share a set of resources to support national decision-making on and implementation for the optimal product, along with resources for the fixed-dose combination (FDC) of pediatric abacavir/lamivudine/dolutegravir (pALD). Please contact HIVToolkit@clintonhealthaccess.org with any questions about the resources listed here.
_JPG.jpg)
_edited.jpg)
.jpg)
pALD Resources
Pediatric abacavir/lamivudine/dolutegravir (pALD) is a new fixed-dose combination (FCD) with DTG that will allow CLHIV to benefit from additional access to the optimal ARV, simplifying supply chain and caregiver administration while continuing to provide the benefits of DTG.
​
CHAI and partners have developed resources to offer clinical overviews, market updates, implementation considerations, and more for national programs considering adopting or transitioning to pALD.
Community Resources
Through the CHAI-Unitaid Optimal Project, which aims to accelerate access to better HIV treatment options, CHAI and AfroCAB established the Optimal Community Advisory Board (CAB) with the goal of fostering engagement with civil society partners to co-develop product adoption strategies and improve understanding of and demand for new ARVs among PLHIV. The CAB includes representatives from a range of global and national PLHIV community and advocacy organizations. The CAB provides strategic direction and leadership to strengthen community engagement in project implementation, to foster demand generation, and to ensure that the CHAI-Unitaid project as a whole supports and complements the activities of the global HIV treatment community. Key pDTG and pALD resources developed by the CAB are highlighted below.
Press & Announcements
Announcements, press releases, and articles related to updates on pDTG and pALD.​
​​
​
Additional press surrounding the pricing announcement and pDTG procurement has been covered in Le Monde, CNN, Daily Mail, New York Times, Reuters, The Telegraph, and AfricaNews, among others.
GAP-f pDTG Task Team Resources
GAP-f is a WHO Network hosted within the Research for Health Department in the Science Division and was created to respond to the paediatric treatment gap. The GAP-f pDTG Task Team is a forum for coordination among partners involved in introduction of pDTG and pALD.
​
The GAP-f Task Team has developed resources, such as the pALD Introduction and Rollout Planning Considerations for National Programmes and GAP-f's pDTG Partner Implementation Guidance (available in English, Spanish, French, Swahili, and Portuguese), which can be accessed below.
